Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab Via Transarterial Chemoembolization (TACE) in Patients With Liver Metastases
NCT06311851Phase 2Active, not recruiting
- Sponsor
- Pardis Noor Medical Imaging and Cancer Center
- Start
- Jun 2025
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in liver metastases, sponsored by Pardis Noor Medical Imaging and Cancer Center. Primary endpoints: Overall Survival Rate at 6 months and Objective Response Rate at 6 months. Started Jun 2025; status: active, not recruiting.
02
Drugs
bevacizumab
03
Conditions
liver metastases
Beyond the preview
Go deeper on NCT06311851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06311851.